Back to Search
Start Over
Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice
- Source :
- Drug Design, Development and Therapy. 13:3657-3667
- Publication Year :
- 2019
- Publisher :
- Informa UK Limited, 2019.
-
Abstract
- Background Diabetic nephropathy (DN) is a common complication of diabetes mellitus (DM) and also a major cause of end-stage renal disease (ESRD). Olmesartan medoxomil (OM) is an angiotensin II receptor blocker (ARB) and has been shown to exhibit renoprotective effects on a streptozotocin (STZ)-induced diabetic rat model. Yet, whether OM affects DN progression and renal injury in db/db mice, a type 2 diabetic murine model, has not been established. Methods Wild-type (n = 15) and db/db mice (n = 15) were treated with control saline or OM via oral gavage. The physiological and biochemical parameters were evaluated and histological examinations of kidney specimens were performed. Results Compared with saline-treated db/db mice, db/db mice administered with OM showed ameliorated diabetic physiological and biochemical parameters. In addition, OM decreased urinary albumin excretion and plasma creatinine level in db/db mice. Moreover, histologically, OM reduced glomerular hypertrophy and injury, and also ameliorated tubular injury, thus suggesting that OM improves renal function and minimizes renal pathological deterioration in db/db mice. Conclusion Our study reveals a beneficial role of OM in ameliorating DN in db/db mice, which is associated with its renoprotective function.
- Subjects :
- 0301 basic medicine
Pharmacology
medicine.medical_specialty
Kidney
Angiotensin receptor
business.industry
Pharmaceutical Science
Renal function
medicine.disease
Streptozotocin
Angiotensin II
Diabetic nephropathy
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
medicine.anatomical_structure
Endocrinology
030220 oncology & carcinogenesis
Internal medicine
Diabetes mellitus
Drug Discovery
Medicine
business
Olmesartan
medicine.drug
Subjects
Details
- ISSN :
- 11778881
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Drug Design, Development and Therapy
- Accession number :
- edsair.doi...........82166134305e9e437e6e5180da532197